GSK said it’s looking to recover “a reasonable royalty” for Moderna’s tens of billions in infringing sales of mRNA vaccines, following similar legal moves made against Pfizer and BioNTech last April.
The UK-based company previously said it was owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales due to patent infringement, claiming Pfizer and BioNTech benefited from mRNA research conducted more than a decade before the pandemic.
GSK said in both suits that it secured the patents to those discoveries in 2015, when it acquired a portion of Novartis’ vaccines business.
“Working under the leadership of vaccinologist Christian Mandl (the ‘Mandl team’), these talented individuals discovered, inter alia, lipid formulations encapsulating mRNA molecules encoding viral protein immunogens that, following administration, provide protection against infection by the corresponding virus,” GSK alleges. “The Mandl team described the inventions now claimed in the Patents-in-Suit, in patent applications filed in 2010.”
From its vaccine Spikevax, Moderna reported more than $24 billion in global revenue in 2022 and 2023, the suit says. A Moderna spokesperson said the company “is aware of the litigation and will defend ourselves against these claims.”
Alnylam also sued both Moderna and Pfizer in 2022 and 2023 related to their vaccine patents.
Check out our mRNA service to expedite your vaccine research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
